These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33862461)

  • 81. Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
    van der Veen JN; Lingrell S; Gao X; Takawale A; Kassiri Z; Vance DE; Jacobs RL
    J Lipid Res; 2017 Apr; 58(4):656-667. PubMed ID: 28159867
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Elucidation of the Metabolic and Transcriptional Responses of an Oriental Herbal Medicine, Bangpungtongseong-san, to Nonalcoholic Fatty Liver Disease in Diet-Induced Obese Mice.
    Choi JY; Kwon EY; Choi MS
    J Med Food; 2019 Sep; 22(9):928-936. PubMed ID: 31390281
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Sophoricoside is a selective LXRβ antagonist with potent therapeutic effects on hepatic steatosis of mice.
    Zhang Y; Li F; Jiang X; Jiang X; Wang Y; Zhang H; Zhang L; Fan S; Xin L; Yang B; Ji G; Huang C
    Phytother Res; 2020 Dec; 34(12):3168-3179. PubMed ID: 32592532
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A multi-targeting strategy to ameliorate high-fat-diet- and fructose-induced (western diet-induced) non-alcoholic fatty liver disease (NAFLD) with supplementation of a mixture of legume ethanol extracts.
    Koh YC; Lin YC; Lee PS; Lu TJ; Lin KY; Pan MH
    Food Funct; 2020 Sep; 11(9):7545-7560. PubMed ID: 32815965
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Psoralea corylifolia L. Seed Extract Attenuates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice.
    Seo E; Oh YS; Jun HS
    Nutrients; 2016 Feb; 8(2):83. PubMed ID: 26861390
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.
    Thrailkill KM; Nyman JS; Bunn RC; Uppuganti S; Thompson KL; Lumpkin CK; Kalaitzoglou E; Fowlkes JL
    Bone; 2017 Jan; 94():141-151. PubMed ID: 27989651
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice.
    Honda Y; Ozaki A; Iwaki M; Kobayashi T; Nogami A; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Yoneda M; Saito S; Nagashima Y; Nakajima A
    J Pharmacol Sci; 2021 Oct; 147(2):176-183. PubMed ID: 34384565
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
    Tahara A
    Eur J Pharmacol; 2021 Jun; 901():174076. PubMed ID: 33798599
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.
    Seko Y; Nishikawa T; Umemura A; Yamaguchi K; Moriguchi M; Yasui K; Kimura M; Iijima H; Hashimoto T; Sumida Y; Okanoue T; Itoh Y
    Diabetes Metab Syndr Obes; 2018; 11():835-843. PubMed ID: 30568471
    [TBL] [Abstract][Full Text] [Related]  

  • 90. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
    Yokono M; Takasu T; Hayashizaki Y; Mitsuoka K; Kihara R; Muramatsu Y; Miyoshi S; Tahara A; Kurosaki E; Li Q; Tomiyama H; Sasamata M; Shibasaki M; Uchiyama Y
    Eur J Pharmacol; 2014 Mar; 727():66-74. PubMed ID: 24486393
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Metabolic phenotype and adipose and liver features in a high-fat Western diet-induced mouse model of obesity-linked NAFLD.
    Luo Y; Burrington CM; Graff EC; Zhang J; Judd RL; Suksaranjit P; Kaewpoowat Q; Davenport SK; O'Neill AM; Greene MW
    Am J Physiol Endocrinol Metab; 2016 Mar; 310(6):E418-39. PubMed ID: 26670487
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease.
    Kontana A; Tziomalos K
    World J Gastroenterol; 2019 Jul; 25(28):3664-3668. PubMed ID: 31391764
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 94. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging.
    Katsuumi G; Shimizu I; Suda M; Yoshida Y; Furihata T; Joki Y; Hsiao CL; Jiaqi L; Fujiki S; Abe M; Sugimoto M; Soga T; Minamino T
    Nat Aging; 2024 Jul; 4(7):926-938. PubMed ID: 38816549
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Celastrol ameliorates liver metabolic damage caused by a high-fat diet through Sirt1.
    Zhang Y; Geng C; Liu X; Li M; Gao M; Liu X; Fang F; Chang Y
    Mol Metab; 2017 Jan; 6(1):138-147. PubMed ID: 28123944
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Integrated omics analysis unraveled the microbiome-mediated effects of Yijin-Tang on hepatosteatosis and insulin resistance in obese mouse.
    Lee JE; Lee SM; Jung J
    Phytomedicine; 2020 Dec; 79():153354. PubMed ID: 32992082
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Sweroside ameliorates NAFLD in high-fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response.
    Yang Q; Shu F; Gong J; Ding P; Cheng R; Li J; Tong R; Ding L; Sun H; Huang W; Wang Z; Yang L
    J Ethnopharmacol; 2020 Jun; 255():112556. PubMed ID: 31926984
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
    Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
    PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
    Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
    J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.